PCN19 Effectiveness and Medical Costs of Abiraterone Acetate Versus Docetaxel in First-LINE Treatment of Metastatic Castration-Resistant Prostate Cancer from the French Nationwide Claims Database (SNDS): Camerra Study
Dec 1, 2020, 00:00
10.1016/j.jval.2020.08.156
https://www.valueinhealthjournal.com/article/S1098-3015(20)32412-8/fulltext
Title :
PCN19 Effectiveness and Medical Costs of Abiraterone Acetate Versus Docetaxel in First-LINE Treatment of Metastatic Castration-Resistant Prostate Cancer from the French Nationwide Claims Database (SNDS): Camerra Study
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(20)32412-8&doi=10.1016/j.jval.2020.08.156
First page :
Section Title :
Open access? :
No
Section Order :
10115